Drug intelligence / Profile preview

Viravaxx RSV vaccine candidate

Development stage: Preclinical
Lead developer: Viravaxx
Modality: Vaccines & Immunotherapeutics

Overview

The Viravaxx RSV vaccine candidate is a preclinical-stage vaccine developed by Viravaxx AG, a Vienna-based biotechnology company. The vaccine is designed to prevent Respiratory Syncytial Virus (RSV) infection by eliciting a protective immune response, potentially involving both antibody and T-cell activation. As of mid-2024, the program was in the preclinical phase of development. However, recent reports indicate that the company's website domain has since expired, suggesting that development may have ceased or the company is no longer active.

Other names: RSV vaccine candidate

Beyond the preview

Go deeper on Viravaxx RSV vaccine candidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viravaxx RSV vaccine candidate.

Explore the full profile